Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 103

Sort by

Sort Order Select

Journal Articles

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

Blood blood.2024026388.

https://doi.org/10.1182/blood.2024026388

Published: 2024

Includes: Supplemental data

Journal Articles

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Blood (2024) 143 (20): 2059–2072.

https://doi.org/10.1182/blood.2023022832

Published: 2024

Includes: Supplemental data

Journal Articles

Novel Agents with Efficacy Against Cellular Models of Familial Platelet Disorder with Myeloid Malignancy (FPD-MM) Associated with Germline Mutant RUNX1

Christopher Peter Mill, Warren C. Fiskus, Courtney D. DiNardo, Patrick K Reville, John Davis, Christine Birdwell, Kaberi Das, Hanxi Hou, Koichi Takahashi, Sanam Loghavi, Joseph D. Khoury, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 2765.

https://doi.org/10.1182/blood-2023-190655

Published: 2023

Journal Articles

Pre-Clinical Efficacy of CDK7 Inhibitor-Based Combinations in Cellular Models of Advanced Myeloproliferative Neoplasms (MPN) Transformed to AML

Warren C. Fiskus, Prithviraj Bose, Lucia Masarova, Christopher Peter Mill, Christine Birdwell, John Davis, Kaberi Das, Hanxi Hou, Taghi Manshouri, Kevin Philip, Noor Alhamadani, Alicia Matthews, Sanam Loghavi, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 1783.

https://doi.org/10.1182/blood-2023-185089

Published: 2023

Journal Articles

Notable Efficacy of Co-Treatment with FHD-286, a Dual BRG1/BRM ATP-Ase Inhibitor, and Menin or BET Inhibitor, Decitabine or Venetoclax Against AML with MLL-r or Mutant NPM1

Warren C. Fiskus, Jessica Piel, Murphy Hentemann, Christopher Peter Mill, Christine Birdwell, Kaberi Das, John Davis, Hanxi Hou, Noor Alhamadani, Kevin Philip, Alicia Matthews, Tapan M. Kadia, Naval Daver, Sanam Loghavi, Branko Cuglievan, Courtney D. DiNardo, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 4160.

https://doi.org/10.1182/blood-2023-182575

Published: 2023

Journal Articles

Targeting BCL-XL with a Novel VHL-Based BCL-XL Degrader DT-2216 in Pre-Clinical JAK2 -Mutant AML Post-MPN Models

Zhe WANG, Qi Zhang, Anna Skwarska, Cassandra L. Ramage, Guangrong Zheng, Kira Gritsman, Kapil N. Bhalla, Naveen Pemmaraju, Daohong Zhou, Jeffrey W Tyner, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4154.

https://doi.org/10.1182/blood-2023-178813

Published: 2023

Journal Articles

Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase

Warren C. Fiskus, Lucia Masarova, Christopher Peter Mill, Christine Birdwell, Kaberi Das, John Davis, Hanxi Hou, Noor Alhamadani, Kevin Philip, Alicia Matthews, Taghi Manshouri, Tapan M. Kadia, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Sanam Loghavi, Marie Törngren, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 741.

https://doi.org/10.1182/blood-2023-185031

Published: 2023

Journal Articles

Actionable Findings from an Unbiased Drug Screen for Novel Single Agent and Combination Therapies Against AML with Mecom Re-Arrangement

Christine Birdwell, Warren C. Fiskus, Christopher Peter Mill, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Koji Sasaki, John Davis, Kaberi Das, Hanxi Hou, Michele Ceribelli, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 1419.

https://doi.org/10.1182/blood-2023-188371

Published: 2023

Journal Articles

Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies

Courtney D. DiNardo, Michael R. Savona, Ashwin Kishtagari, Amir T. Fathi, Kapil N. Bhalla, Samuel Agresta, Sarah Reilly, Caroline Almon, Murphy Hentemann, Denice Hickman, Dillon Corrigan, Meghan Macaraeg, Jessica Piel, Kim Horrigan, Salah Nabhan, Paul Martin, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 4284.

https://doi.org/10.1182/blood-2023-178090

Published: 2023

Journal Articles

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)

Lucia Masarova, Hagop M. Kantarjian, Naveen Pemmaraju, Hussein A Abbas, Prithviraj Bose, Mahesh Swaminathan, Sherry Pierce, Koji Sasaki, Musa Yilmaz, Nicholas J. Short, Naval Daver, Gautam Borthakur, Guillermo Garcia-Manero, Maro Ohanian, Kapil N. Bhalla, Courtney D. DiNardo, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4264.

https://doi.org/10.1182/blood-2023-187968

Published: 2023

Journal Articles

Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background

Warren C. Fiskus, Jessica Piel, Murphy Hentemann, Christopher Peter Mill, Christine E Birdwell, Kaberi Das, John A. Davis, Noor Alhamadani, Kevin Philip, Tapan M. Kadia, Naval Daver, Sanam Loghavi, Courtney D. DiNardo, Kapil N. Bhalla

Blood (2022) 140 (Supplement 1): 8819–8820.

https://doi.org/10.1182/blood-2022-164513

Published: 2022

Journal Articles

Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression

Christine E Birdwell, Warren C. Fiskus, Tapan M. Kadia, Christopher Peter Mill, John A. Davis, Kaberi Das, Naval Daver, Courtney D. DiNardo, Koichi Takahashi, Koji Sasaki, Stephen Horrigan, Kapil N. Bhalla

Blood (2022) 140 (Supplement 1): 493–494.

https://doi.org/10.1182/blood-2022-170715

Published: 2022

Journal Articles

Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

Yannan Jia, Lina Han, Cassandra L Ramage, Connie C. Weng, Lei Yang, Simona Colla, Helen Ma, Weiguo Zhang, Michael Andreeff, Naval Daver, Nitin Jain, Naveen Pemmaraju, Kapil N. Bhalla, Satu Mustjoki, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Qi Zhang, Marina Konopleva

Blood (2022) 140 (Supplement 1): 3347–3349.

https://doi.org/10.1182/blood-2022-164541

Published: 2022

Journal Articles

Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1

Christopher Peter Mill, Warren C. Fiskus, John A. Davis, Kaberi Das, Christine E Birdwell, Tapan M. Kadia, Koji Sasaki, Koichi Takahashi, Courtney D. DiNardo, Sanam Loghavi, Naval Daver, Kapil N. Bhalla

Blood (2022) 140 (Supplement 1): 5860–5861.

https://doi.org/10.1182/blood-2022-169584

Published: 2022

Journal Articles

Bruton's Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors

Warren C. Fiskus, Kaberi Das, Christopher Peter Mill, Christine E Birdwell, John A. Davis, Noor Alhamadani, Kevin Philip, May Tan, Robert A Brown, Michael R Green, Kapil N. Bhalla

Blood (2022) 140 (Supplement 1): 5980–5981.

https://doi.org/10.1182/blood-2022-168483

Published: 2022

Journal Articles

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

Blood (2022) 140 (Supplement 1): 9041–9043.

https://doi.org/10.1182/blood-2022-168029

Published: 2022

Journal Articles

Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53

Warren C. Fiskus, Kaberi Das, Christopher Peter Mill, Christine E Birdwell, John A. Davis, Kevin Philip, Noor Alhamadani, Tapan M. Kadia, Naval Daver, Koji Sasaki, Koichi Takahashi, Sanam Loghavi, Courtney D. DiNardo, Jesse Vargas, Kapil N. Bhalla

Blood (2022) 140 (Supplement 1): 8807–8808.

https://doi.org/10.1182/blood-2022-165012

Published: 2022

Journal Articles

Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2

Christopher P. Mill, Warren Fiskus, Courtney D. DiNardo, Christine Birdwell, John A. Davis, Tapan M. Kadia, Koichi Takahashi, Nicholas Short, Naval Daver, Maro Ohanian, Gautam Borthakur, Steven M. Kornblau, Michael R. Green, Yuan Qi, Xiaoping Su, Joseph D. Khoury, Kapil N. Bhalla

Blood (2022) 139 (6): 907–921.

https://doi.org/10.1182/blood.2021013156

Published: 2022

Includes: Supplemental data

Journal Articles

Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood (2021) 138 (Supplement 1): 367.

https://doi.org/10.1182/blood-2021-147360

Published: 2021

Journal Articles

NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2021) 138 (Supplement 1): 2287.

https://doi.org/10.1182/blood-2021-154059

Published: 2021

NARROW

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Novel Agents with Efficacy Against Cellular Models of Familial Platelet Disorder with Myeloid Malignancy (FPD-MM) Associated with Germline Mutant RUNX1

Pre-Clinical Efficacy of CDK7 Inhibitor-Based Combinations in Cellular Models of Advanced Myeloproliferative Neoplasms (MPN) Transformed to AML

Notable Efficacy of Co-Treatment with FHD-286, a Dual BRG1/BRM ATP-Ase Inhibitor, and Menin or BET Inhibitor, Decitabine or Venetoclax Against AML with MLL-r or Mutant NPM1

Targeting BCL-XL with a Novel VHL-Based BCL-XL Degrader DT-2216 in Pre-Clinical JAK2 -Mutant AML Post-MPN Models

Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase

Actionable Findings from an Unbiased Drug Screen for Novel Single Agent and Combination Therapies Against AML with Mecom Re-Arrangement

Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)

Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background

Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression

Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1

Bruton's Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53

Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2

Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only